50mg vial
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys complexed with Cu²⁺), first isolated from human plasma in 1973. Endogenous plasma levels decline from approx. 200 ng/mL at age 20 to approx. 80 ng/mL by age 60 - a decline correlated with reduced tissue-repair capacity. Transcriptome analysis shows GHK-Cu modulates expression of over 4,000 genes involved in tissue remodelling.
Checking availability…
Acts as a biological signal of tissue damage - triggering stem cell activation, chemoattraction of repair cells, upregulation of collagen I/III/IV synthesis and broad transcriptome-level remodelling. Copper chelation also drives potent antioxidant activity via SOD stimulation.
Topical (most common): 1–5% serum or cream, once or twice daily to target area. Injectable research protocols: 1–2mg subcutaneously or intradermally, 2–3× weekly to target area; systemic SC at 1–3mg/day. Cycles typically run 8–12 weeks.
Plasma approx. 0.5–1 hour; tissue residence and biological effect persists for days to weeks.
Reconstitute a 50mg vial with 5mL bacteriostatic water for a 10mg/mL working concentration. The solution will appear blue-green - this is the copper complex and is expected.
Lyophilised: room temperature acceptable short-term; 2–8°C for long-term (stable 12–24 months). Reconstituted: 2–8°C, protect from direct light, use within 60 days. Blue-green colour does not indicate degradation.